Avitech and Fox Chase collaborate on gene tests:
This article was originally published in Clinica
Executive Summary
Avitech Diagnostics and the Fox Chase Cancer Center in Philadelphia are collaborating on the development of cancer tests. The two organisations will attempt to use CEL-1, an enzyme discovered at Fox Chase, to develop tests for mutations in the breast cancer genes, BRCA1 & 2; the tumour suppressor, p53; and the hereditary colon cancer gene, msh2.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.